Table 1.
Demographics and baseline characteristicsa
| Idelalisib | |
|---|---|
| N = 25b | |
| Male, n (%) | 11 (44) |
| Race, n (%) | |
| White | 19 (76) |
| Black or African American | 2 (8) |
| Asian | 1 (4) |
| Other | 3 (12) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (12) |
| Not Hispanic or Latino | 22 (88) |
| Agec, years, median (range) | 42 (21–80) |
| BMId, kg/m2, mean (SD) | 25 (5.94) |
| ECOG performance status, n (%) | |
| 0 | 10 (40) |
| 1 | 10 (40) |
| 2 | 1 (4) |
| Missing | 4 (16) |
| Time since diagnosise, years, mean (SD) | 3.9 (4.26) |
| Prior therapies, median (range) | 5 (2–9) |
| Type of previous treatment, n (%) | |
| BV | 23 (92) |
| ASCT | 18 (72) |
| Radiation therapy | 11 (44) |
| Classical HL pathologic subtype, n (%) | |
| Nodular sclerosis | 23 (92) |
| Lymphocyte rich | 2 (8) |
| Disease stage at screening, n (%) | |
| I–II | 9 (36) |
| III–IV | 16 (64) |
a
The population used for this analysis includes all patients in the intent-to-treat set who received ≥1 dose of idelalisib.
b
Includes all patients treated during this study.
c
Age (years) = (date of first dose of study medication – date of birth + 1)/365.25.
d
BMI (kg/m2) = weight/height2.
e
Time since diagnosis is calculated in months as (date of randomization to the primary study – date of diagnosis)/30.4375.
ASCT, autologous stem cell transplant; BMI, body mass index; BV, brentuximab vedotin; ECOG, Eastern Cooperative Oncology Group; HL, Hodgkin lymphoma; SD, standard deviation.